Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population

American Journal of Clinical Pathology

Volumn 143, Issue 1, 2015, Pages 126-133

  Castle, Philip E ^a   Smith, Katherine M ^b   Davis, Thomas E ^c   Schmeler, Kathleen M ^d   Ferris, Daron G ^e   Savage, Ashlyn H ^f   Gray, Jermaine E ^g   Stoler, Mark H ^h   Wright, Thomas C ⁱ   Ferenczy, Alex ^j   Einstein, Mark H ^k  

^a Global Cancer Initiative   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e AUGUSTA UNIVERSITY   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ Columbia University ^*  (United States)

^j MCGILL UNIVERSITY   (Canada)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Microbiology; Molecular diagnostics; Virology

Indexed keywords

VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER GRADING; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; UNITED STATES; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; MOLECULAR DIAGNOSIS; PAPILLOMAVIRUS INFECTIONS; PATIENT REFERRAL; PROCEDURES; REPRODUCIBILITY; UTERINE CERVICAL NEOPLASMS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; FEMALE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRUS INFECTIONS; REFERRAL AND CONSULTATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84923557905     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP4Q0NSDHWIZGU     Document Type: Article

References (25)

1. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012; 62: 147-172.
2. Massad LS, Einstein MH, Huh WK, et al. 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013. 17 S1-S27.
3. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention. Geneva, Switzerland: World Health Organization; 2013. Available at http://apps.who.int/iris/bitstream/10665/94830/1/9789241548694-eng.pdf
4. Stoler MH, Castle PE, Solomon D, et al. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007; 127: 1-3.
5. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009; 124: 516-520.
6. Meyer-Rath G, Schnippel K, Long L, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One. 2012; 7: e36966.
7. Einstein MH, Smith KM, Davis TE, et al. Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy. J Clin Microbiol. 2014: 52: 2089-2095.
8. Castle PE, Solomon D, Wheeler CM, et al. Human papillomavirus genotype specificity of Hybrid Capture 2. J Clin Microbiol. 2008; 46: 2595-2604.
9. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11: 1048-1056.
10. Dalstein V, Riethmuller D, Pretet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer. 2003; 106: 396-403.
11. Snijders PJ, Hogewoning CJ, Hesselink AT, et al. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV. 16, 18, 31 and 33-positive women with normal cytology. Int J Cancer. 2006; 119: 1102-1107.
12. Xi LF, Kiviat NB, Galloway DA, et al. Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3. J Infect Dis. 2008; 198: 324-331.
13. Xi LF, Hughes JP, Castle PE, et al. Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis. 2011; 203: 1425-1433.
14. Gravitt PE, Kovacic MB, Herrero R, et al. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer. 2007; 121: 2787-2793.
15. Castle PE, Schiffman M, Scott DR, et al. Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1311-1314.
16. Pretet JL, Dalstein V, Monnier-Benoit S, et al. High risk HPV load estimated by Hybrid Capture II(®) correlates with HPV16 load measured by real-Time PCR in cervical smears of HPV16-infected women. J Clin Virol. 2004; 31: 140-147.
17. Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet. 2002; 360: 228-229.
18. Hesselink AT, Berkhof J, Heideman DA, et al. High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer. Int J Cancer. 2009; 124: 381-386.
19. Koss LG. The Papanicolaou test for cervical cancer detection: a triumph and a tragedy. JAMA. 1989; 261: 737-743.
20. Kovacic MB, Castle PE, Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 2006; 66: 10112-10119.
21. Bigras G, de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in. 13, 842 women. Br J Cancer. 2005; 93: 575-581.
22. Carozzi FM, Del Mistro A, Confortini M, et al. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting. Am J Clin Pathol. 2005; 124: 716-721.
23. Castle PE, Wheeler CM, Solomon D, et al. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol. 2004; 122: 238-245.
24. Castle PE, Lorincz AT, Mielzynska-Lohnas I, et al. Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J Clin Microbiol. 2002; 40: 1088-1090.
25. Heideman DA, Hesselink AT, Berkhof J, et al. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol. 2011; 49: 3983-3985.